Microbiome Therapeutics - Global Market Trajectory & Analytics

Global Microbiome Therapeutics Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Microbiome Therapeutics estimated at US$46 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 58.1% over the analysis period 2020-2027. Type 2 Diabetes, one of the segments analyzed in the report, is projected to record a 66.4% CAGR and reach US$244.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 59% CAGR for the next 7-year period.



The U.S. Market is Estimated at $14.1 Million, While China is Forecast to Grow at 54.6% CAGR

The Microbiome Therapeutics market in the U.S. is estimated at US$14.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$172.9 Million by the year 2027 trailing a CAGR of 54.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 53.1% and 48.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.

C. Difficile Infection Segment to Record 49.1% CAGR

In the global C. Difficile Infection segment, USA, Canada, Japan, China and Europe will drive the 49.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$13.7 Million in the year 2020 will reach a projected size of US$224.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$135.8 Million by the year 2027.

Select Competitors (Total 46 Featured):

• 4D pharma plc
• AOBiome
• Enterome SA
• Evelo Biosciences, Inc.
• Ferring International
• Immuron Ltd.
• LNC Therapeutics
• Microbiome Therapeutics, LLC.
• Osel, Inc.
• OxThera AB
• Rebiotix, Inc.
• Ritter Pharmaceuticals, Inc.
• Second Genome
• Seres Therapeutics, Inc.
• Vedanta Biosciences, Inc.
• ViThera Pharmaceuticals, Inc.